Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Shiu‐Feng Huang, Il‐Chi Chang, Chih‐Chen Hong, Tseng‐Chang Yen, Chao‐Long Chen, Cheng‐Chung Wu, Cheng‐Chung Tsai, Ming‐Chih Ho, Wei‐Chen Lee, Hsien‐Chung Yu, Ying‐Ying Shen, Hock‐Liew Eng, John Wang, Hui‐Hwa Tseng, Yung‐Ming Jeng, Chau‐Ting Yeh, Chi‐Ling Chen, Pei‐Jer Chen, Yun‐Fan Liaw – 18 April 2018 – Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies.

Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort

Domenico Tricò, Sonia Caprio, Giuseppina Rosaria Umano, Bridget Pierpont, Jessica Nouws, Alfonso Galderisi, Grace Kim, Mariana M. Mata, Nicola Santoro – 17 April 2018 – We conducted a prospective study in a large, multiethnic cohort of obese adolescents to characterize clinical and genetic features associated with pediatric nonalcoholic fatty liver (NAFL), the most common cause of chronic liver disease in youth. A total of 503 obese adolescents were enrolled, including 191 (38.0%) whites, 134 (26.6%) blacks, and 178 (35.4%) Hispanics.

The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility

Lin Lee Wong, Holly F Fisher, Deborah D Stocken, Stephen Rice, Amardeep Khanna, Michael A Heneghan, Ye Htun Oo, George Mells, Stuart Kendrick, Jessica Katharine Dyson, David E. J. Jones, on behalf of the UK‐AIH Consortium – 17 April 2018 – Patient reporting suggests that the physical and psychological effects of autoimmune hepatitis (AIH) can be substantial. However, health‐related quality of life (HRQOL) in patients with AIH remains incompletely characterized, and health utility remains to be explored.

Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant

Jasmohan S. Bajaj, Genta Kakiyama, Tor Savidge, Hajime Takei, Zain A. Kassam, Andrew Fagan, Edith A. Gavis, William M. Pandak, Hiroshi Nittono, Phillip B. Hylemon, Prapaporn Boonma, Anthony Haag, Douglas M. Heuman, Michael Fuchs, Binu John, Masoumeh Sikaroodi, Patrick M. Gillevet – 17 April 2018 – Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis.

Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu – 17 April 2018 – Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival benefits with sorafenib.

Subscribe to